Supernus Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 41.84 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.43B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizu...